Biopharma Dealmaking Bounced Back In A Big Way In 2025

 
• By Joseph Haas and Nancy Pham
  
2025 marked a return to normalcy for biopharma dealmaking, with increased activity in M&A and alliances (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business